

Anti-CTLA-8/IL-17a Antibody (Xeligekimab)

Introduction



Xeligekimab (GR 1501) is a humanized monoclonal antibody against human interleukin 17A (IL-17A). Xeligekimab inhibits the pro-inflammatory cascade.

Product parameters

| Alternative Names | Xeligekimab |
|----------------------|---|
| Target Accession | Q16552 |
| Target | CTLA-8 / IL-17a |
| CAS number | 2382921-73-3 |
| Molecular Weight | 147.34 kDa |
| Host | СНО |
| Reactivity | Human |
| Conjugation | Unconjugated A P E X B () |
| Form Achieve Perfect | Liquid Achard Particition, Explore the Unknown |
| Concentration | See label |
| Buffer System | 100 mM Pro 20 mM Arg pH 5.0. No preservative! |
| Clonality | Monoclonal |
| Purification | - |
| Isotype | IgG4SP |
| Application | ELISA, FACS, Kinetics, Functional assay, Animal Model |
| Biological activity | - |
| Endotoxin | Less than 0.1 EU/ug determined by LAL method. |
| Sterilization | 0.2 μM filtered |
| Reconstitution | For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration Gently shake it to solubilize the protein completely. Do not vortex. |
| Shipping | Dry ice |
| Storage | -80 ℃ |
| Expiration Date | 2 years |
| Note | Please avoid freeze-thaw cycles. |

Note

1. This product is for scientific research use only.









